Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of ANRO is 30 and suggests 97% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell